0001562180-20-006582.txt : 20201106
0001562180-20-006582.hdr.sgml : 20201106
20201106164737
ACCESSION NUMBER: 0001562180-20-006582
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20201104
FILED AS OF DATE: 20201106
DATE AS OF CHANGE: 20201106
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hippel James
CENTRAL INDEX KEY: 0001603594
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-17272
FILM NUMBER: 201295064
MAIL ADDRESS:
STREET 1: 614 MCKINLEY PLACE NE
CITY: MINNEAPOLIS
STATE: MN
ZIP: 55413
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIO-TECHNE Corp
CENTRAL INDEX KEY: 0000842023
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 411427402
STATE OF INCORPORATION: MN
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 614 MCKINLEY PL N E
CITY: MINNEAPOLIS
STATE: MN
ZIP: 55413
BUSINESS PHONE: 6123798854
MAIL ADDRESS:
STREET 1: 614 MCKINLEY PLACE NE
CITY: MINNEAPOLIS
STATE: MN
ZIP: 55413
FORMER COMPANY:
FORMER CONFORMED NAME: TECHNE CORP /MN/
DATE OF NAME CHANGE: 19920703
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2020-11-04
false
0000842023
BIO-TECHNE Corp
TECH
0001603594
Hippel James
614 MCKINLEY PLACE N.E.
MINNEAPOLIS
MN
55413
false
true
false
false
Chief Financial Officer
Common Stock
2020-11-04
4
M
false
7100.00
108.49
A
16237.00
D
Common Stock
2020-11-04
4
S
false
1555.00
272.7099
D
14682.00
D
Common Stock
2020-11-04
4
S
false
2745.00
273.6454
D
11937.00
D
Common Stock
2020-11-04
4
S
false
1600.00
274.534
D
10337.00
D
Common Stock
2020-11-04
4
S
false
1200.00
275.7931
D
9137.00
D
Common Stock
2020-11-05
4
M
false
8809.00
108.49
A
17946.00
D
Common Stock
2020-11-05
4
S
false
398.00
280.277
D
17548.00
D
Common Stock
2020-11-05
4
S
false
203.00
281.2741
D
17345.00
D
Common Stock
2020-11-05
4
S
false
1674.00
282.5203
D
15671.00
D
Common Stock
2020-11-05
4
S
false
325.00
283.64
D
15346.00
D
Common Stock
2020-11-05
4
S
false
1630.00
285.1165
D
13716.00
D
Common Stock
2020-11-05
4
S
false
121.00
287.1493
D
13595.00
D
Common Stock
2020-11-05
4
S
false
3249.00
287.9804
D
10346.00
D
Common Stock
2020-11-05
4
S
false
359.00
289.3858
D
9987.00
D
Common Stock
2020-11-05
4
S
false
750.00
291.0627
D
9237.00
D
Common Stock
2020-11-05
4
S
false
100.00
293.66
D
9137.00
D
Stock Option (Right to Buy)
108.49
2020-11-04
4
M
false
7100.00
0.00
D
2022-08-07
Common Stock
7100.00
7100.00
D
Stock Option (Right to Buy)
108.49
2020-10-05
4
M
false
8809.00
0.00
D
2022-08-07
Common Stock
8809.00
0.00
D
Stock Option (Right to Buy)
106.59
2023-08-18
Common Stock
30400.00
30400.00
D
Stock Options (Right to Buy)
106.59
2023-08-18
Common Stock
40533.00
40533.00
D
Stock Options (Right to buy)
125.05
2024-08-09
Common Stock
24460.00
24460.00
D
Stock Options (Right to Buy)
125.05
2024-08-09
Common Stock
32613.00
32613.00
D
Restricted Stock Units
Common Stock
3383.00
3383.00
D
Stock Options (Right to buy)
177.32
2025-08-08
Common Stock
18066.00
18066.00
D
Stock Options (Right to Buy)
177.32
2025-08-08
Common Stock
24089.00
24089.00
D
Restricted Stock Units
Common Stock
3938.00
3938.00
D
Stock Option (Right to Buy)
190.41
2026-08-07
Common Stock
19936.00
19936.00
D
Stock Options (Right to Buy)
190.41
2026-08-07
Common Stock
26581.00
26581.00
D
Restricted Stock Unit
Common Stock
3219.00
3219.00
D
Stock Option (Right to Buy)
267.87
2027-08-05
Common Stock
14360.00
14360.00
D
Stock Options (Right to Buy)
267.87
2027-08-05
Common Stock
19147.00
19147.00
D
Stock Options (Right to buy)
267.87
2027-08-05
Common Stock
8325.00
8325.00
D
Stock Options (Right to buy)
267.87
2027-08-05
Common Stock
8325.00
8325.00
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $272.21 to $273.20, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $273.23 to $274.19, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.24 to $275.045, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $275.38 to $276.30, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $279.84 to $280.80, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $281.00 to $281.55, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $282.00 to $282.78, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $283.57 to $284.48, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $285.00 to $285.89, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $286.67 to $287.25, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $287.68 to $288.46, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $289.00 to $289.58, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $290.66 to $291.40, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $293.66 to $293.66, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Fully exercisable.
Options to purchase 8,153 shares vest on each of 8/9/2018, 8/9/2019, 8/9/2020 and options to purchase 8,154 shares vest on 8/9/2021.
Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.
Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Options to purchase 6,023 shares vest on 8/8/2019 and options to purchase 6,022 shares vest on each of 8/8/2020, 8/8/2021 and 8/8/2022.
Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Options to purchase 6,646 shares vest on 8/7/2020 and options to purchase 6,645 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023.
Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator.
Options to purchase 4,787 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023 and options to purchase 4,786 shares vest on 8/5/2024.
Options to purchase 2,775 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.
Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.
/s/ Brenda S. Furlow, attorney in fact for James Hippel pursuant to Power of Attorney previously filed
2020-11-06
EX-24
2
hippelpoa2017.txt
HIPPELPOA2017
POWER OF ATTORNEY
The undersigned hereby constitutes and
appoints Brenda S. Furlow, Anna Weispfenning,
Melodie R. Rose, Andrew Nick, Sarah Tucher or
either of them acting alone, the
undersigned's true and lawful attorneys-in-
fact and agent with full power of
substitution and resubstitution, for the
undersigned and in the undersigned's name,
place and stead, in any and all capacities,
to sign any or all Forms 3, Forms 4 and
Forms 5 relating to beneficial ownership of
securities of Bio-Techne Corporation (the
"Issuer"), to file the same, with all
exhibits thereto and other documents in
connection therewith, with the Securities and
Exchange Commission and to deliver a copy of
the same to the Issuer, granting unto said
attorney-in-fact and agent full power and
authority to do and perform each and every
act and thing requisite and necessary to be
done in and about the premises, as fully to
all intents and purposes as the undersigned
might or could do in person, hereby ratifying
and confirming all said attorneys-in-fact and
agent, or his substitute or substitutes, may
lawfully do or cause to be done by virtue
thereof. The undersigned acknowledges that
the foregoing attorney-in-fact, in serving in
such capacity at the request of the
undersigned, is not assuming any of the
undersigned's responsibilities to comply with
Section 16 of the Securities Exchange Act of
1934.
This Power of Attorney shall remain in
effect until such time as the undersigned is
no longer subject to the provisions of
Section 16 of the Securities Exchange Act of
1934 with respect to securities of the
Issuer.
IN WITNESS WHEREOF, the undersigned has
caused this Power of Attorney to be executed
as of this 3rd day of October, 2017.
/s/ James Hippel